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ABSTRACT
Obesity is a serious health problem in Western society, affecting up to 35% of the
adult population in the United States and is associated with cardiovascular disease, non-
insulin dependent diabetes mellitus, and increased risk of many forms of cancer. Obesity
is recognized as a disorder of energy bal,ance, having genetic components, which
develops when energy intake through feeding exceeds energy expenditure. Regulation of
feeding occurs throu~h the hypothalamic regulation of two main- pathways, the catabolic
or melanocortin pathway, and the anabolic or neuropeptide Y pathway. Evidence in
rodent models shows that mutations in genes coding for neuropeptides and neuropeptide
receptors in these pathways can cause obesity in rodents. Mutations in ortholog genes in
humans may similarly be a cause of human obesity. Recent evidence has found that
mutations in the melanocortin pathway in humans are either silent or occur at a frequency
of less than 1%. The rate of mutations were examined in the genes coding for receptors
involved in the anabolic pathway, specifically neuropeptide Y receptors Yl and Y5. In
r
addition, tissue specific expression patterns of the alternatively spliced forms of NPY Yl
and Y5 receptor mRNAs were determined. Three separate heterozygous mutations were
identified in the coding regions of both receptor genes. These mutations, however, were
either synonymous (silent) or rare, occurring at a frequency less than 1%, providing
indirect evidence that obesity in humans is not caused by these genes. Tissue specific
expression analysis showed that expression of the Y5 receptor gene is localized primarily
to the brain whereas the expression of the Yl receptor occurs in the brain as well as
peripheral tissues and is regulated by three alternatively spliced 5' exons.
Introduction
Obesity is a serious health problem in Western society, affecting up to 35% of the
adult population in the United States. Obesity is associated with morbidity in
cardiovascular disease, non-insulin dependent diabetes mellitus, osteoarthritis and
increased risk of many forms of cancer. Once thought to be a social disease which could
be treated with appropriate diet and exercise regimens, obesity is now recognized as a
disorder of energy balance having genetic components, which develops when energy
intake exceeds energy expenditure. Energy intake and energy expenditure are largely
regulated by the central nervous system(CNS), particularly the hypothalamus
(Strader, 1997). Afferent signals from the periphery communicate information about the
metabolic and nutritional status to the CNS. The CNS responds to these afferent signals
by altering the levels of several neurotransmitters, thereby generating efferent signals that
alter appetite and energy expenditure.
Traditionally, control of energy intake has been the approach to the control of
obesity. Over the past few years, however, the role of en~rgy expenditure in the control
of oqesity has become increasingly apparent. Weight loss is difficult to maintain by
control of energy intake alone, suggesting that body weight tends to stabilize at a
physiological set point that is difficult to alter (Leibel,1995). When energy intake alone
is controlled, the body responds...by controlling its energy expenditure in a compensatory
direction. Therefore, successful treatment of obesity,must regulate the mechanisms that
- , .
control both energy intake and energy expenditure.
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Leptin and the Leptin Receptors
Recent experiments in both mouse and human models have provided evidence
that has helped to unravel several genetic components that regulate obesity. The cloning
of the ob gene and the demonstration that its protein hormone product, leptin, is secreted
by adipocytes in the periphery and acts on the CNS to regulate body weight helped in the
understanding of body weight control (Campfield, 1995). Further observations showed
that leptin plays a central role in coordinating both food intake and satiety as well as
regulation of energy expenditure (Woods, 1998). This hormone has both long term and
short term affects on feeding. In the long term, this hormone conveys to the
hypothalamus information about the 'size of energy stores and activates hypothalamic
centers that regulate energy intake and expenditure (Flier, 1997). In addition, leptin
affects several neuroendocrine mechanisms that regulate multiple hypothalamic-pituitary
axes (Flier, 1997).
This hormone also acts in the short term, following periods of feeding and fasting,
independent of energy stores. In humans, following periods of fasting, plasma leptin
levels are decreased, much more than the amount of adipose tissue lost (Lonnqvist,
1995). Leptin and ob gene mRNA levels during periods of fasting and feeding suggests
that serum leptin is regulated by energy availability. This regulation is not immediate,
however, and the adaptive response of leptin to energy availability is mediated through
changes in serum insulin and fatty acids (Considine, 1996). Leptin levels reflect not only
the amount of fat stored, but also energy imbalance; prolonged fasting decreases leptin
levels, whereas overfeeding increases them (Tritos, 1997). The composition of the diet
also controls circulating leptin levels. In addition, prolonged insulin infusions increase
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leptin levels. Therefore, the control of feeding occurs through both long term and short
term mechanisms that controlleptin levels.
The mouse leptin gene consists of 3 exons and two introns and encodes a 4.5 Kb
spliced mRNA (Zhang, 1994). Two different mutations in the mouse gene have been
found to date, one of which abolishes the leptin gene transcription, the ob/ob genotype,
and the other which results in a truncated, inactive form of the protein (Zhang, 1994).
Mice with this ob/ob genotype are obese (Zhang, 1994). Later experiments showed that
infusion of leptin into ob/ob mice eliminated obesity (Halaas, 1995). This discovery
raised the question as to whether obesity in humans could also be due to a deficiency in
leptin production.
Human leptin is 84% homologous to the mouse protein. Recently, the first two
individuals with mutated leptin genes resulting in inactive proteins have been discovered
(Montague, 1997). However, an obese population DNA screening has failed to
demonstrate a high incidence of mutations within the leptin gene, indicating that
mutations in the leptin gene are a rare cause of obesity in humans (Considine, 1995 &
Niki, 1996). It appears that obesity in humans may be a leptin-resistant rather than a
leptin-deficient state (Considine, 1996).
One possibility for this resistance may be due to defective leptin receptors. In the
mouse, six alternatively spliced forms of the leptin receptor are known (Gwo-H~a,
1996). The two major splice variants are the short (Ob-R-S) and the long (Ob-R·L)
forms (Gwo-Hwa, 1996). The short form is expressed in a variety of tissues, with the
highest number of receptors found in the mouse choroid plexus and leptomeninges (Gwo-
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Hwa, 1996). These receptors transport leptininto the cerebrospinal fluid, but not into the
brain interstitial fluid which bathes the brain receptors (Lonnqvist, 1999).
The second receptor form, the long form, is expressed at high leyels in the
hypothalamus (Gwo-Hwa, 1996). In order for leptin to reach the hypothalamus, it must
be transported across the blood-brain barrier. This active transport across the blood-brain
barrier occurs through a saturable, specific temperature dependent process that occurs via
a dual process which includes binding and enddcytosis (Golden, 1997). Because of the
fact that the ratio of leptin concentrations between the serum and cerebrospinal fluid is
much lower in obese mice, a decreased transportation efficiency across the blood-brain
barrier could be one of the major factors that contribute to obesity (Schwartz, 1996).
In humans, however, a deficiency of the leptin receptor does not appear to be a
cause of obesity. Although sequence mutations were discovered in the human leptin-
receptor gene during population screening, most translated into silent mutations
(Clement, 1998). There was, however a single base substitution that caused the change
of a glutamine for an arginine. This mutation, however was found in both lean and obese
individuals and most subjects were heterozygous for the mutation. Because most cases of
human obesity are not associated with defective leptin or leptin-receptor genes, it is
possible that a defect in the leptin signaling pathway may be the cause of obesity in
humans.
Leptin circulates in the plasma in a free or bound form. Plasma leptin levels
increase with increasing fat mass (Lonnqvist, 1995). Leptin levels reflect not only the
amount of adipocytes, but also energy imbalance. Prolonged fasting decreases leptin
levels whereas overeating greatly increases them (Kolaczynski, 1996). In addition to
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diet, adiposity, and energy balance, a number of intrinsic adipocyte factors as well as
several cytokines may regulate leptin expression and circulating levels in humans
(Mantzoros, 1998).
Leptin acts by activating specific leptin receptor isoforms which, as in the mouse,
include a long and several short forms (Tartaglia, 1997). In humans, long leptin receptors
are found in many areas of the brain, including the hypothalamus, cerebellum, and
hippocampus (Steiner, 1996). The long leptin receptor isoform activates transcription
and alters expression of many hypothalamic neuropeptides which are involved in two
different types of feeding systems.
The first system is termed catabolic and is activated by high levels of leptin
during positive energy balance. This system, exemplified by the melanocortin system,
decreases food intake and increases energy expenditure to facilitate the loss of excess
energy stores. The second system is termed anabolic and is activated by low levels of
leptin during negative energy balance. This system, exemplified by the neuropeptide Y
system, increases food intake and decreases energy expenditure to facilitate the regaining
of lost energy stores. Activation of these neuropeptides starts a cascade of events which
ultimately leads to modifications in energy intake and expenditure.
Catabolic Pathway of Feeding
In the first case, under obese conditions, the increased amount of adipose tissue
corresponds to higher levels of peripheralleptin. Increased leptin causes the release of
Melanocyte stimulating hormone (MSH) from the hypothalamus. MSH binds to the
melanocortin-4 receptor in the hypothalamus and causes reduced food intake as well as
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increased energy expenditure and sympathetic activity (Friedman, 1997). In other words,
higher leptin levels lead to a state in which energy expenditure exceeds food intake.
In this case, when higher levels of leptin exist as a result of increased adipocytes,
.the melanocortin receptor pathway is activated and a decrease in food intake results
(Woods, 1998). There are five known melanocortin receptors in the mouse. All of these
receptors bind the peptide hormone class of melanocyte stimulating honnones (MSH).
These peptide hormones are derived from pro-opiomelanocortin (POMC), a prohormone
that is processed into three classes of honnones; the melanocortins, adrenocorticotropin
hormone (ACTH), and various endorphins (Cone, 1996). Evidence for the role of the
melanocortin pathway in feeding comes from mouse models.
The melanocortin-1-receptor (MC1R) has been shown to be involved in coat
color whereas the Melanocortin-4-receptor (MC4R) has been shown to be involved with
signal transduction in the hypothalamus (Satoh, 1998). Hypothalamic MC4R as well as
the MC1R signaling is blocked in Agouti mutant mice by ectopic expression of the Agouti
peptide (Lu, 1994). The Agouti peptide causes a yellow skin, obese phenotype. A MC4R
knockout mouse was made to assess the role of MC4R in the regulation of weight
homeostasis. These mice have identical phenotypes as the Agouti mice, develop age-
onset obesity, with the exception of the coat color, verifying the separate roles of the MC-
1 and MC-4 receptors (Huszar, 1997). Under normal conditions, binding of leptin to the
Ob-R-L in the hypothalamus causes the production of POMC. POMC is then converted
to melanocortin which binds to the MC4R. Binding of melanocortin to the MC4R causes
a cascade of unknown events which reduces feeding.
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Even though this pathway is poorly characterized in humans, it is believed that
mutations in genes causing monogenetic forms ofobesity in rodents are implicated in
similar syndromes in humans (Montague, 1997). It is possible to think that mutations in
the MC4R are responsible for obesity in humans. Factors dbwnstream of the MC4R have
not yet been identified. Recent research therefore has concentrated on determining
whether mutations in the MC4R gene exist, and if so, at what frequency in the obese
population. Several studies indicate thatpolymorphisms within the coding region of the
MC4R receptor are unlikely to be a common cause of obesity in humans due to the low
frequency of functionally significant mutations (Gu, 1999 & Hinney, 1999). Therefore,
until factors downstream of the MC4R have been identified, it will be difficult to tie
polymorphisms within the MC4R pathway to the development of obesity in humans.
However, it is possible that polymorphisms within the coding regions of the NPY
receptor genes, which are also known to be affected by leptin and have a role in feeding,
may be the cause of early onset obesity in humans.
Anabolic Pathway .of Feeding
In this pathway, during starvation, lower amounts of adipose tissue correspond to
lower levels of leptin being released from this tissue as an afferent signal. Levels of leptin
receptor mRNA and leptin binding are increased in the hypothalamus during fasting,
principally in NPY neurons (Baskin, 1999). Leptin binding causes the activation of the
Neuropeptide Y (NPY) pathway. Increased levels of NPY are released from the
hypothalamus and NPY binds to both the NPY 1 and NPY5 receptors, causing a cascade
of poorly understood events which increase food intake and decrease energy expenditure.
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Neuropeptide Y, a 36 residue peptide, is known to participate in vascular tone,
feeding, inhibition of seizures and in neuropeptide and anterior pituitary hormone
secretion. NPYis expressed predominantly in the central nervous system and is one of
the most abundant neuropeptides in the brain (W$lestedt, 1993); Central administration
of NPY exerts a powerful feeding stimulus and influences body energy homeostasis by
affecting insulin secretion, hepatic glucose output and lipoprotein lipase activity (Kalra,
1997). In addition, mice deficient in NPY show a significant increase in susceptibility to
seizures, suggesting that NPY may be an endogenous anticonvulsant. These diverse
physiological actions are mediated through distinct NPY receptor subtypes (Yinghe,
1996). NPY receptors, like the MC4R and the leptin receptor, belong to the large
superfamily of G-protein-coupled receptors (GPCRs).
GPCRs are a superfamily of seven transmembrane domain proteins. They are
found in a wide range of organisms and are involved in the transmission of signals to the
interior of the cell via interaction with a G-protein. All GPCRs are thought to operate
through a similar molecular mechanism. The binding of an extracellular ligand to
GPCRs causes poorly understood conformational changes. These conformational
changes promote the association of the GPCR with distinct classes of heterotrimeric G-
proteins. This association activates these G-proteins which are then free to interact with
effector enzymes and ion channels (Wess, 1998).
Six subtypes of NPY receptor have been cloned, showing a large degree of
sequence variation. These receptors have been studied most extensively in rodents where
.
it was shown that ligands that preferentially bind NPY Yl and Y5 receptors stimulate
feeding whereas most Yl and Y5 antagonists have been shown to inhibit food intake
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(Oshea, 1997). In addition, pharmacological data suggest that NPY's stimulatory effect
on appetite is transduced by the NPY Y5 receptor (Oshea, 1997). The evidence suggests
that NPY increases food intake by binding the Yl and Y5 receptors.
Additional evidence for t~e role of NPY in feeding comes from rodent studies. In
these animals it has been observed that leptin administration represses NPY production in
the hypothalamus in response to fasting (Billington, 1991). Other evidence comes from
the observation that chronic administration of NPY into the hypothalamus rapidly leads
to obesity in rodents (Stanley, 1986). Finally, NPY signalling is elevated in the
hypothalamus of leptin deficient mice ( Stephens, 1995 & Schwartz, 1996). Because of
these results, the NPY receptors are potential candidates for the control of obesity in
humans.
The human NPY Y5 receptor has 88% homology to the rat NPY Y5 receptor. In
humans, neurons of the hypothalamic arcuate nucleus exert both stimulatory and
inhibitory effects on food intake and both NPY Yl and Y5 mRNA are highly expressed
at this site (Woldbye,1998). These results, in addition to the data obtained from rat
studies, make the NPY Yl and Y5 receptors excellent candidates for drug development·
against obesity as well as excellent candidates for polymorphic analysis.
The human NPY Yl and Y5 receptor are transcribed from a common promoter
region in opposite directions (Herzog,1997), (Fig.l). Both genes are alternatively
spliced. To date, three alternatively spliced 5' exons of Yl(Herzog,1997), and five
alternatively spliced 5' exons of Y5 have been discovered (Parker, 1999) which allow for
the regulation of tissue specific expression. In all cases, these exons encode part of the 5'
. ~
untranslated region (Herzog, 1997 & Parker, 1999) .
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Overlapping gene structures of Neuropeptide Yl and Y5 receptors
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Figure 1. The human Neuropeptide Y I and Y5 gene cluster as adapted from Herzog (1997). The coding region of both
genes are shown as black vertical lines. Noncoding sequences are shown as blue boxes for Y5 and green boxes for Yl.
Exon IC of Y I is part of the coding region of Y5 and is indicated by green and blue horizontal lines.
v I
One of the alternatively spliced exons of Yl (IC) is also contained in the coding
region of Y5, and is transcribed from the opposite strand. In addition, both alternatively
spliced Y5 exons (lA and IB) are in close proximity to exon IB of NPY Yl.
Transcription of both genes from the same promoter region suggests the possibility that
transcriptional activation of one will have an effect on the regulation of expression of the
other. As both receptors are thought to playa role in the regulation of food intake
through NPY, coordinating expression of these two genes will be important in controlling
the effect of NPY. Transcription of Yl exon lC may have a direct inhibitory effect on
the expression of Y5. This is supported by the fact that expression of the Yl receptor is
reported in the colon, kidney, adrenal gland, pancreas, placenta and brain whereas Y5
expression is reported only in the brain and testes (Ball, 1995).
Differences in tissue expression of the alternatively spliced exons of NPY Yl
have been studied in artery and kidney cells as well as a neuroblastoma cellline(SK-N-
Me). RT-PCR analysis of the RNA from these tissues, using primers specific for the
alternatively spliced exons, shows differential expression of the isoforms (Ewing, 1998).
However, the analysis was limited to these three tissues. Other experiments studied the
differences in tissue expression of the alternatively spliced exons of NPY (Parker et
al.;1999). These experiments, however, had limited success. These researchers looked in
several brain regions including the hippocampus, hypothalamus, thalamus and cortex
using RT--rCR analysis. This analysis, however, could not specifically distinguish
between the five different isoforms. In addition, these researchers found that their
subcloning and sequencing results contradicted their RT-PCR results.
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Research problem
At this time very little is known about the tissue specific expression of the coding
regions of both the Yl and Y5 receptor genes as well as the alternatively spliced exons
of the Yl receptor. In addition, a polymorphi~m analysis of the coding regions of both
genes is needed to determine whether a high incidence of mutations are observed in the
population and if so, whether these mutations predispose an individual to obesity. In
. J
order to study the occurrence of mutations in the two receptor genes, genomic DNA will
be isolated from the whole blood from patients suffering from schizophrenia and unstable
angina. A polymorphism analysis of the neuropeptide Y Yl and Y5 receptor genes from
each patient DNA sample will be performed by first PCR amplifying the genes and then
performing direct sequencing from the PCR products. This sequence will then be
analyzed for polymorphisms using several alignment programs. The tissue specific
expression of the two receptors will be studied by first performing a multiple tissue dot
blot on the coding regions of the two receptor genes and then a multiple tissue northern
analysis on both the coding regions of the two receptors and the a~ternati vely spliced 5'
exons of neuropeptide Y Yl receptor gene.
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Materials and Methods
Isolation of Genomic DNA from Blood
A collaboration between Merck & Co. and various hospitals around the United
States was set up in order for Merck to obtain blood samples from patients suffering from
both unstable angina and schizophrenia. Samples were shipped to Merck overnight after
being drawn and lymphoid cells were isolated immediately. In most cases, the lymphoid
cells were isolated and frozen at _700 C within 24 hours after the blood was drawn..
Approximately 9 milliliters of blood was transferred to a 50 milliliter falcon tube. An
equal volume of Phosphate Buffered Saline (PBS), pH 7.4 was added to the tube and
gently mixed by inversion. In a separate 50 milliliter falcon tube the blood was slowly
and carefully layered onto 15 milliliters of Ficoll-Plaque Plus (Pharmacia Biotech). The
ficoll creates a gradient when centrifuged that separates the lymph and white blood cells
from the red blood cells. The sample was spun at 1200 rpm for 30 minutes at room
temperature in a Beckman GS-6 centrifuge. The lymphoid cells at the ficoillmedia
interface were collected and placed into a clean 50 ml falcon tube containing 10
milliliters PBS (pH 7.4). The tube was mixed gently and centrifuged for 10 minutes at
2000 rpm in a Beckman GS-6 centrifuge. The supernatant was discarded and the pellet
containing lymphoid cells was resuspended in 1 ml PBS (pH 7.4) and aliquotted into 3
separate 1.5 ml eppendorf tubes. The eppendorf tubes were spun at 2000 rpm for 10 min
in a bench-top centrifuge and the supernatant is discarded. These samples were' then
stored at -700 C until they are needed for DNA isolation.
For the isolation of the genomic DNA from the lymphoid cells, 2 milliliters of
lysis buffer (lOmM Tris-HCI pH 7.5, 400mM NaCl, 2mM EDTA) was placed in a 15
14
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milliliter falcon conical tube. The lymphoid cells which were frozen at -70° C are placed
on ice to thaw. These cells were then added to the lysis buffer. Immediately, 330
microliters of Proteinase K (lOmglml) and 133 microliters 10% SDS was added. The
tube was inverted several times gently and incubated overnight (16-18 hours) at 50° C.
This tube was then allowed to cool to room temperature and 667 microliters saturated
NaCI (Approximately 6M) was added. The tube was inverted several times and spun at
3,000 rpm for 30 min in a Beckman OS-6 centrifuge. The supernatant was transferred to
a clean 15 ml Falcon tube using a pipette-man PlOOO. Two volumes of 100% EtOH were
added and the sample was spun at 3,000 rpm for 30 minutes at 4° C using a refrigerated
Beckman OS-6 centrifuge. The supernatant was poured off and the sample was air dried
for 20 minutes and r~suspended in 400 microliters of TE (10 roM Tris, pH 8.0, 1 roM
EDTA), quantitated and stored at 4° C for use in PCR.
Design and synthesis of peR primers
PCR primers (Table 1) were designed to amplify the coding regions of both the
NPY Yl and Y5 receptor genes (Figures 2 and 3). In addition, a tail was added to the
primers to perform direct sequencing off the PCR product. These primers were
synthesized on an Applied Biosystems 394 DNA synthesizer at 0.2 micromolar scale
with the trityl group automatically removed. After synthesis, the primers were heated at
65° C for one hour and then transferred to two eppendorf tubes in which they were dried
down at high speed in a table-top speed-vac. After being dried down completely, the
primers were resuspended in 100 microliters of water, quantitated and diluted to a
concentration of 20 pmol. These primers were then used to set up a PCR reaction using
genomic DNA isolated from the whole blood.
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PRIMER DESIGNATION SEQUENCE
------------------------------------------------------------_ ..-----....------------------------------------------------------------
YI-IA 5'-GTT GTA AAACGA CGG CCA GTC ATA CTG TCC ATT TGT CTA A
L
Yi-IB 5'-GCT ATG ACC ATG ATT ACG CCA TGT CTA TTA TTT GGT CTC C
YI-2A 5'-GTT GTA AAA CGA CGG CCA GTC TCA GAC TTG CTT GTT GCC A
YI-2B 5'-GCT ATG ACC ATG ATT ACG CCC CAT CAT GTT GTT TCT CCT TTT TAG
YI-3A 5'-GTT GTA AAA CGA CGG CCA GTT TCC ATT TTT ACC TTC TTT ACA CAG·
YI-3B 5'-GCT ATG ACC ATG ATT ACG CCT GGG AGA ACA GGT AAT CAA AGT ATG
Y5-1A 5'-GTT GTA AAA CGA CGG CCA GTT GTA ATG TTT TTT TGG TTG CTG
Y5-lB 5'-GCT ATG ACC ATG ATT ACGCCCAGATGGCAAAAC CTAGTGTCC
Y5-2A 5'-GTT GTA AAA CGA CGG CCA GTT GCC ATT GTC AGG TAT CAT A
Y5-2B 5'-GCT ATG ACC ATG ATT ACG CCA CTG GAT GAA GAG AGC TGA C
Y5-3A 5' -GTT GTA AAA CGA CGG CCA GTG TGG GCC TCA GGT GAA ACT C
Y5-3B 5'-GCT ATG ACC ATG ATT ACG CCT GAC CCC AGC ATT TGT TCT T
Table 1. PCR primers used to amplify the coding regions of the Neuropeptide Y Yl and Y5
receptor genes. Underlined sequence represents the primer tail which will be used for direct sequencing.
These underlined bases represent sequencing priming sites..
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Figure 2. Black arrows indicate PCR primers designed to amplify the coding region of the NPY Yl receptor.
Overlapping PCR products ensure complete coverage. Exon 2 and Exon 3 are the blue boxes shown on the genomic DNA.
Red horizontal lines indicate PCR product location. Red vertical lines are stop codons and the green P's indicate start codons
as the genomic DNA is translated into all three frames. Exon 2 is in frame three and Exon three is in frame 1.
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Figure 3. Black arrows indicate peR primers designed to amplify the coding region of the NPY Y5 receptor.
Overlapping PCR products ensure complete coverage. Exon 2 is the blue box shown on the genorruc DNA.
Red horizontal lines indicate PCR product location. Red vertical lines are stop codons and the green P's indicate
start codons as the genomic DNA is translated into all three frames. Exon 2 is in frame 1.
Amplification of the Yl and YS receptor genes
The three primer sets for each of the two receptor genes were used to amplify the
coding regions by PCR. .The PCR reaction included 50 ng of genomic DNA, 5.0 ul of
lOX PCR buffer (Perkin Elmer) (lOOmM Tris-HCI pH 8.3, 500mM KCI, 15mM MgCh,
0.01 % gelatin), 4.0 u12.5mM dNTP's(Gibco), 1.0 ul of each 20 pmol primer, 0.25 ul of
TaqGold (5ulul) (Perkin Elmer), and water to 50 ul. Reactions were set up at room
temperature and then placed in a MJ Research PTC-225 thermocycler for cycling.
Cycling conditions for all peR reactions were 94° C for 12 minutes, and then 35 cycles at
94° C for 30 seconds, 60° C for 30 seconds, and 68° C for 90 seconds. The last
parameter was 1 cycle at 68° C for 5 minutes. PCR reactions were set up on 32 patients
at a time in a Perkin Elmer cycling plate (Robbins). In total, over 200 patient samples
were used for amplification and analysis (Table 2).
peR reaction purification
All PCR reactions were immediately purified on a Qiagen Biorobot 9600, using a
modified Qiagen protocol. Each set of 32 PCR reactions were purified separately. Four
eight-strip Qiaquick strips were placed into Qiavac manifold. The 50 ul PCR reaction
was combined with 250 ul buffer PBTM and added to the Qiaquick wells. A vacuum was
then applied to the manifold until all the liquid has passed through the column. The
vacuum is then switched off and the wells were washed with 1 ml of buffer PE™ two
times. In each case the yacuum was applied until all PE passes through the column.
After the second wash the vacuum was applied for an additional 5 minutes to dry the
membrane. The vacuum was turned off and the manifold and columns were dried with a
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GENDER AND ETHNICITY BACKGROUND ON PATIENTS USED IN SNP ANALYSIS
Study category.
Tactics Patients l)Male
2)Female
Patient Information
,.
A)Caucasian
B)J3lack
C)Asian
p)Hispanic
E)Other
A)Caucasian
B)Black
C)Asian
D)Hispanic
E)Other
54
6
2
6
2
26
7
o
3
o
Schizophrenia Patients 1)Schizophrenic
2)Control(Non-Schizophrenic)
48
48
Table 2. The gender and ethnicity background for the tactics patients as
well as the control vs. schizophrenic breakdown for the schizophrenia patient set.
Tactic patients all suffer from unstable angina.
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paper towel to ensure all ethanol has been removed from the strips. The manifold and
strips were then placed over collection tubes and the DNA was eluted from the columns
using 80 ul buffer EB(lOmM Tris-CI, pH 8.5) and collected in the collection tubes. This
DNA was then run on an agarose gel to verify the presence ofa produce and used for
direct sequencing using Bodipy sequencing chemistry.
peR verification using agar.ose gels
A 100mi solution of 1% agarose was made by adding 1 gram agarose
(GibcoBRL), 10 ml of lOX TBE(8.9 M Tris, 8.9 M Borate, 0.02 M EDTA) and 2.5 ul of
EtBr(lOmg/ml). Before adding the EtBr, the rest of the components were microwaved on
high for 3 minutes and allowed to cool to approximately 60° C before the EtBr was added
and poured into a gel casting tray with two twenty well combs. 5 ul of the PCR product
was combined with 2 ul of loading buffer(40 % sucrose, 0.25 mg/ml Bromophenol Blue,
0.25 mg/ml Zylene cyanol) and loaded onto the 1% agarose gel and run for 1 hour at 150
volts. All 32 patients were run with a negative PCR control(no DNA) and a phiX 174
marker(GibcoBRL). A picture of this gel containing PCR products from 32 patients was
then taken for documentation (Figure 4).
Bodipy Primer synthesis
Primers were synthesized for sequencing off the purified PCR products. These
primers were synthesized on an Applied Biosystems 394 DNA synthesizer at 1.0
micromolar scale with the trityl group left on. The final synthesis step included the
addition of either a C3 or a C6 amino modifier which would allow for the addition of a
Bodipy Dye (Figure 5 and Table 3), After synthesis, the C3 primers were heated at 37° C
21
AAgarose gel verification of peR products
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Figure 4. peR products from patients 1-32 run on a 1% agarose gel with a PhiX 174 marker. Gel A
represents patient amplification using primer set Yl-lA and YI-lB. Gel B represents patient
amplification using primer set Y5-1A and Y5-lB. Marker (M) and Negative control(B)are marked
along with the 32 patients.
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Figure 4. peR products from patients 1-32 run on a 1% agarose gel with a PhiX 174 marker. Gel A
represents patient amplification using primer set Y I-I A and Y I-I B. Gel B represents patient
amplification using primer set Y5- rA and Y5-1 B. Marker (M) and Negati ve control(B )are marked
along with the 32 patients. .
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Bodipy Dye Chemistry
BODIPY 5031512
~
BODIPY 564/570
BODIPY 523/547
BODIPY 5811S91
Figure 5. Chemical structures of the four Bodipy dyes for automated DNA sequencing.
All structures are obtained from Science Vol. 271 Pg 1420. .
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SEQUENCING PRIMERS USED FOR BODIPY SEQUENCING
PRIMER DESIGNATION SEQUENCE
---------------------------------------------------------------------------------------------------------------------
MRL 41 C6-TTG TAA AAC GAC GGC CAG T
MRL 42 C3-TTG TAA AAC GAC GGC CAG T
MRL 88 C6-TAT GAC CAT GAT TAC GCC
MRL 89 C3-TAT GAC CAT GATTAC GCC
Table 3. Sequencing primers used to sequence directly from the PCR products. One of
four Bodipy dy.es are added to this C3 or C6 amino modifier.
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for 24 hours and the C6 primers were heated at 65° C for one hour and then 20 ul of 0.5M
NaOH was added to each primer and each primer was transferred to two eppendotf tubes
in which they were dried down at high speed in a table-top speed-vac. After being dried
down completely, the primers were resuspended in 160 microliters of water and
transferred to a 2 ml eppendotf tube. To each tube, 640 ul of glacial acetic acid was
added, mixed and incubated at room temperature for 30 minutes. Each sample was split
into two tubes and to each tube, 200 ul of 10 N NaOH and 1240 ul of 100% EtOH was
added. The samples were vortexed and centrifuged at 14,000 rpm for 5 minutes. The
supernatant was decanted and to the C6 primers, 300 ul of 0.25 M NaHC03 was added to
each tube and the sample was split into three tubes. 5 ul of the respective Bodipy dye
(PE Applied Biosystems) was added to one of the three tubes (503/512, 523/547,
564/570). For C3 primers, ~OO ul of 0.25 M NaHC03 was added to each tube. The tubes
were combined and 5 ul of Bodipy 581/591 dye was added. The dyeswere incubated for
16 hours at room temperature in the dark. For C6 primers, 20.5 ul of 3M sodium acetate
(pH 5.2) and 451 ul of 100% EtOH was added. For C3 primers, 40.5 ul of sodium acetate
(pH 5.2) and 851 ul of 100% EtOH was added. The tubes were centrifuged for 15
minutes at 14,000 rpm, the supernatant was poured off and the pellets were washed three
times with 70% EtOH for 2 mi'nutes at 14,000 rpm. The C6 primers were dissolved in 20
ul of lOmM TEAA and C3 primers were dissolved in 30 ul of lOmM Triethylamine
Acetate, pH 7.0 (TEAA). The primers were then purified using a Beckman Biosys 510
HPLC and an Applied Biosystems 250x4.6mm Aquapore RP-300 7 micron column
(Figures 6-13). After purification, the primers were diluted to 0.4 pmol/ul using .water.
Bodipy Sequencing
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HPl·r trace of MRL 41 (503/512) purification
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Figure 6. HPLC trace ofMRL 41 (503/512) purification.
Elution off of the HPLC column was measured at a wavelength of
260. The arrows indicate the primer peak that was collected.
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HPLC trace ofMRL 41 (523/547) purification
,- Figure 7. HPLC trace ofMRL 41 (523/547) purification.
Elution off of the HPLC column was measured at a wavelength of
260. The arrows indicate the primer peak that was collected.
27
HPLC trace of MRL 41 (564/570) purification
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Figure 8. HPLC trace of MRL 41 (564/570) purification.
Elution off of the HPLC column was measured at a wavelength of
260. The arrows indicate the primer peak that was collected.
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HPLC trace of MRL 42 (581/591) purification
Figure 9. IiPLC trace of MRL 42 (581/591) purification.
Elution off of the HPLC column was measured at a wavelength of
260. The arrows indicate the primer peak that was collected.
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HPLC trace of MRL 88 (503/512) purification
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Figure 10. HPLC trace of MRL 88 (503/512) purification.
Elution off of the HPLC column was measured at a wavelength of
260. The arrows indicate the primer peak that was col1ected.
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Figure 11. HPLC trace of MRL 88 (523/547) purification.
Elution off of the HPLC column was measured at a wavelength of
260. The arrows indicate the primer peak that was collected.
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HPLC trace of MRL 88 (564/570) purification
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Figure 12. HPLC trace of MRL 88 (564/570) purification.
Elution off of the HPLC column was measured at a wavelength of
260. The arrows indicate the primer peak that was collected.
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HPLC trace ofMRL 89 (581/591) purification
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Figure 13. HPLC trace of MRL 89 (581/591) purification.
Elution off of the HPLC column was measured at a wavelength of
260. The arrows indicate the primer peak that was collected.
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Approximately ~OOng of purified PCR product was used in Taq FS sequ~ncing reactions
using custom primers labeled With Bodipy dyes.. Sequencing of a PCR product included
both a forward and a reverse reaction, each of which is set up separately. ~eactions were
set up on a Beckman Biomek 2000 robot using Dye-Primer chemistry, where each di-
deoxynucleotide reaction was set up in a separate reaction (Chadwick, 1996). Each
reaction was set up in a volume of 8 ul. This included 2 ul of PCR DNA(100ng/ul), 1 ul
of the appropriate Dye Primer (0.4 pmol/ul), luI of the appropriate di-deoxynucleotide
mix (0.5 rnM each of the 3 deoxynucleotides and 1.5uM of the di-deoxynucleotide with
the exception of ddATP which was 0.75 uM) and 2 ul of dilute Taq FS buffer (20 mM
Tris-HCI, pH 9.0, 0.50 mM MgCh, 4.2 units Taq FS). Reactions were then centrifuged
briefly and placed in a MJ Research PTC-225 thermocycler for cycling. Cycling
conditions were 20 cycles at 94° C for 10 seconds, 60° C for 20 seconds, and 70° C for
one minute. Follo;wing cycling, all. four reactions(A,C,G,T) were pooled and precipitated
using 80 ul of ice cold 100% EtOH and spun at 3000 rpm for 30 minutes at 4° C in a
bench-top Beckman GS-6R centrifuge. The EtOH was removed and the samples were
dried for 10 minutes on low heat in a speed-vac.. Samples were then resuspended in 3 ul
98% formamide, 10 mM EDTA (Fisher Scientific). After resuspension, these samples
were heated at 68° C for 3 minutes before loading onto a sequencing gel.
Sequencing Gels
All Bodipy samples were run on a 48 centimeter 4.5% polyacrylamide gel which
was made from 36% Urea, 4.5 % Long Ranger (FMC Bioproducts), IX TBE(.89 M Tris,
.89 M Borate, .002 M EDTA), .05% Ammonium PerSulfate(Biorad) and .0007%
TEMED (Biorad) for 10 hours on an Applied Biosystems 377 DNA Sequencer.
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Sequence Analysis
The forward and reverse reads of sequenced PCR products were assembled using
Sequencher assembly program(Ewiing, 1998). In addition, all sequencing reads on the
three PCR products for each patient were assembled using this program (Figure 14).
After this was done, the sequence chromatogram was analyzed by eye for any possible
mistakes. After this was done the consensus sequence of the patients for both the Y1 and
Y5 receptor genes were compared to finCl any single nucleotide polymorphisms (SNPs)
(Figure 15-16).
Northern Analysis Probe Synthesis
Probes to perform a northern analysis on the coding regions of Neuropeptide Y
/ .
Y1 'and Y5 were selected by comparing the three PCR products covering both the Y1 and
Y5 receptor genes against the National Center for Biotechnology Information (NCBI)
nucleotide and protein databases. The comparisons were done in all six frames and the
PCR product from Y1-1A and Y1-1B was selected as a probe for the coding region of Y1
and the Y5-1A and Y5-1B PCR product was selected as a probe against Y5. In both
cases, only the corresponding gene contained these specific sequences.
The PCR reaction to generate the probe included 50 ng of genomic DNA, 5.0 ul
of lOX PCR buffer (Perkin Elmer) (lOOmM Tris-HCl pH 8.3, 500mM KCl, 15mM
-MgCh, 0.01% gelatin), 4.0 u12.5mM dNTP's(Gibco), 1.0 ul of each 20 pniol primer,
0.25 ul of TaqGold (5u/ul) (Perkin Elmer), and water to 50 ul. Reactions were set up at
room temperature and then placed in a MJ ResearchPTC~225 thermocycler for cycling.
Cycling conditions for all PCR reactions were 94° C for 12 minutes, and then 35 cycles at
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Neuropeptide Y Y5 Receptor Sequence Assembly
Il" - - - - - np528a.2425.s:0020jan9912.abi
np528a.2425.r2020jan9912.abi
E (
np528a.2627.s0025jan99d2.abi
) )
np528a.2627 .r2025jan99d2.abi-
E (
IJJ
0\
np528a-3031.r2022jan99d2.abi
E. (
np528a-3031 .s0005feb99f2.abi) )
1 461 543 847 1))12 1~424Y
I r r r rr r H r r r f '1 I
I I r r I I II II I II II Ir I I I I I I I rll I I I if" I III ~ r I i'i' I ~
I I I I I III I I II i'fl II r I r I II I I II I I 1111 I
Figure 14. Alignment of t he forward and reverse sequencing reads for all three peR products covering the coding
region of Neuropeptide Y Y5 receptor of patient np528a. Alignment was done in Sequencher.
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Figure 15. Alignment of forward and reverse sequence reads covering the NPY Yl
receptor coding region. Green arrows correspond to forward reads and red arrows
correspond to reverse reads.
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..~ 001 A-NPY 1
..~ 892 A-NPY 1
..~ 1219-NP'r'1
..~ 114A-NP'r'1 C.
..~ 0380-NP'r'1
..~ 0378-NP'r'1
..~ 244A-NP'r'1
..~ 3397-NPY 1C.
..~ 06045-NPY 1
..~ 225A-NP'r'1
..~ 16092-NP'r'1
..~ 0391-NP'r'1
..~ 989A-NPY1(. ..
..~ 3095-NPY 1
..~ 3297-NPYI
..~ 508A-NPYI
..~ 546A-NPYI
~ I..~ 571 A-NPYI
..~ 3548-NPY 1
..~ 850A-NPYI
..~ 413A-NPYI
..~ 3572-NPYI
..~ 357 A-NPY 1
..~ 0341 -NPY 1
..~ 528A-NPYI C.
..~ 549A-NPYI
..~ 1608 A-NPY 1
..~ 704A-NPYI
..~ 445A-NPYI
..~ 2703-NPYI
..~ 395 A-NPY 1
..~ 721 A-NPY 1
Alignment of consensus sequences
Summary
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAfl~
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG TGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf'
AATTTCCATCGGACTCTCRTAGGTTGTCTTATACCRCTCTCCTCTTG GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCRTCGGACTCTCATRGGTTGTCTTATRCCACTCTCCTCTTG GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
,AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG TGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG'I GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTGiGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTGfGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG. GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG - GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAF
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG .~.TGCTGCAGTATTTTGGTCCACTTTGTTTT.ATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGA~TCTCATAGGTTGTCTTATACCACTCTCCTCTTGiTGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTGITGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAfAATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTGI~GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTGITGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTGIrGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTGITGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAF
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTGi" GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG , GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
.
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTGITGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGfTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG~'.".TGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG " GCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG~TGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAF
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTGITGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAf
AATTTCCATCGGACTCTCATAGGTTGTCTTATACCACTCTCCTCTTG~TGCTGCAGTATTTTGGTCCACTTTGTTTTATATTTATTTGCTACTTCAF'
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Figure 16. Alignment of the consensus sequences of the Neuropeptide Y YI receptor
gene from 32 patients. The blue horizontal line indicates a position where patient 3397
has a nucleotide variation from the other patients.
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Consensus Alignment-NPY Y5
Summary
TGGATGTTTGGCAAAGTCATGTGCCATATTATGCCTTTTCTTCAAITGTGTCAGTTTTGGTTTCAACTTTAATTTTAATATCAATTGCCATT
TGGATGTTTGGCAAAGTCATGTGCCATATTATGCCTTTTCTTCAA TGTGTCAGTTTTGGTTTCAACTTTAATTTTAATATCAATTGCCATT
TGGATGTTTGGCAAAGTCATGTGCCATATTATGCCTTTTCTTCAA TGTGTCAGTTTTGGTTTCAACTTTAATTTTAATATCAATTGCCATT j;lifi
TGGATGTTTGGCAAAGTCATGTGCCATATTA,GCCTTTTCTTCAA,.. ·. TGTGTCAGTTTTGGTTTCAACTTTAATTTTAATATCAATTGCCATT mill
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~:~~~~~~~~~ liIl!1
TGGATGTTTGGCAAAGTCATGTGCCATATTATGCCTTTTCTTCAA. TGTGTCAGTTTTGGTTTCAACTTTAATTTTAATATCAATTGCCATTII
TGGATGTTTGGCAAAGTCATGTGCCATATTATGCCTTTTCTTCAA,.~TGTGTCAGTTTTGGTTTCAACTTTAATTTTAATATCAATTGCCATT !imi
TGGATG TT TGGC AA AGTCAT GT GCCATATTAT GCC TTT TCTTCAA!jib TG TGTCAGTTTTGGTTT CAACTTTAATTTTAATATCAATTGCCATT 11~m
TGGATGTTTGGCAAAGTCATGTGCCATATTATGCCTTTTCTTCAAtTGTGTCAGTTTTGGTTTCAACTTTAATTTTAATATCAATTGCCATT mm
~~~~~~~~~~~~~:~~~~:~~~~~~:~~~~:~~~~~~~~~~~~~:~~:~:~~::~~~~::~~~~~~~~~~::~~~~:~~:~~~~~~:~~:~~II
TGGATGTTTGGCAAAGTCATGTGCCATATTATGCCTTTTCTTCAAj:;TGTGTCAGTTTTGGTTTCAACTTTAATTTTAATATCAATTGCCATT mi!i
TGGATGTTTGGCAAAGTCATGTGCCATATTATGCCTTTTCTTCAA~TGTGTCAGTTTTGGTTTCAACTTTAATTTTAATATCAATTGCCATTII
TGGATGTTTGGCAAAGTCATGTGCCATATTATGCCTTTTCTTCAAi!iPTGTGTCAGTTTTGGTTTCAACTTTAATTTTAATATCAATTGCCATT lim,
TGGATGTTTGGCAAAGTCATGTGCCATATTATGCCTTTTCTTCAAE'.·c: TGTGTCAGTTTTGGTTT'CAACTTTAATTTTAATATCAATTGCCATT Him
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Figure 17. Alignment of the consensus sequences of the Neuropeptide Y Y5 receptor
gene from 32 patients. The blue horizontal line indicates a position where patient 528A
has a nucleotide variation from the other patients
94° C for 30 seconds, 60° C for 30 seconds, and 68° C for 90 seconds. The last
parameter was 1 cycle at 68° C for 5 minutes. PCR reactions were set up on 32 patients
at a time in a Perkin Elmer cycling plate (Robbins). PCR products were purified on the
Qiagen robot as explained earlier and then run on a 1% agarose gel as explained earlier.
The PCR product was then subcloned into Invitrogen's pCR-BluIit II-TOPO
vector (Figure 17) using their Zero Blunt TOPO PCR cloning kit. In this cloning
reaction, 4 ul of PCR product (200ng) is mixed with 1 ul of pCR-Blunt II-TOPO vector
and incubated for five minutes at room temperature. After incubating the reaction, 2 ul is
transformed into Invitrogen's TOPlO competent cells (F mrcA mrr-hsdRMS-mcrBC
phi80lacZ':Ml5lacX74 recAI deoR araD139 ara-Ieu7697 galU galK rpsL (Stl) endAI
nupG). This was done by adding 2 ul 0.5 M Beta-mercaptoethanol tothe vial of
competent cells. After 10 minutes, 2. ul of the TOPO cloning reaction was added on ice.
to the competent cells. The reaction was incubated for 30 minutes on ice and then placed
at 42° C for 30 seconds and back on ice for 2 minutes. Afterincubating on ice for 2
minutes; 250 ul of room temperature SOC (2% Tryptone, 0.5% yeast extract, 0.06%
NaCI, 0.02%'KCI, 0.2% MgCh, 0.25% MgS04) was added to the tube and the tube was
then shaken for 1 hour at 37° C. After incubating for 1 hour, 50 ul of the reaction was
spread onto a LB plate with 1.5% Agar (Gibco) and 50ug/ml Kanamycin (Sigma). Plates
...
were incubated overnight at 37° C. Single colonies were picked and placed into a 5ml
, culture of LB with 50 ug/ml Kanamycin and grown overnight while shaking at 37° C.
Cultures were then centrifuges for 10 minutes at 3,000rpn{in a Beckman J6-MI
t
centrifuge. The supernatant was poured off and the DNA was extracted and purified
from the pellets using the Qiagen robot and the mini-prep protocol.
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Invitrogen's PCR Cloning Vector
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Figure 18. PCR products were cloned into Invitrogen's pCR-Blunt II-TOPO vector for
amplification. Inserts were later removed using the EeoRI restriction sites.
The bacterial pellet is resuspended in 250 ul of buffer PI (.606% Tris Base,
.372% NAzEDTA, pH8.0 and .lmg/ml Rnase A). 250 ul of buffer P2 (0.8% NaOH, 1%
SDS) is added to the tube and the tube is gently mixed by inversion six times. The
reaction is incubated for five minutes at room temperature. After incubating for five
minutes, 350 ul of buffer N3 (29.4% potassium acetate, pH5.5) is added to the sample
and the reaction is mixed by inversion and transferred into a Qiagen turbofilter plate. A
vacuum is applied to the QIAprep plate until all the samples have passed through. The
QIAprep plate is then washed with 0.9ml buffer PE (unknown salts, 80% EtOH) several
times. The DNA is eluted using 125 ul water.
One ug of the sample is then digested using EcoRI restriction enzyme to isolate
the purified insert and the insert is gel extracted for use in the northern analysis. A 50 ul
reaction is set up using 1.0 ug of DNA, 5 ul of Promega buffer H (450mM Tris-HCI, 50
mM MgClz, 250mM NaCI, pH7.5), and 3 ul of EcoRI (12u1ul). The reaction was
incubated for three hours at 37° C and then placed on ice.
A 100mi solution of 1% agarose is made by adding 1 gram agarose (GibcoBRL),
10 ml of lOX TBE (8.9 M Tris, 8.9 M Borate, 0.02 M EDTA) and 2.5 ul of EtBr
(lOmg/ml). Before adding the EtBr, the rest of the components are microwaved on high
for 3 minutes and allowed to cool to approximately 60° C before the EtBr is added and
poured into a gel casting tray with two twenty well combs. All 50 ul of the digest is
combined with 10 ul of loading buffer (40 % sucrose, 0.25 mg/ml BromophenolBlue,
0.25 mg/ml Zylene cyanol) and loaded onto the 1% agarose gel and run for 1 hour at 150
volts.
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The band of interest was cut out of the gel using a clean razor and placed into an
eppendorf tube. The gel slice was weighed and 3 volumes of buffer QG™ to 1 volume of
gel slice was added. The tube was incubated for 10 minutes at 50° C. One gel volume of
100% isopropanol was added and the tube is mixed by inversion. The sample was
applied to a QIAquick column and the column was spun at 14,000rpm for 1 minute. The
flow through was discarded and the column was washed with 0.75 ml buffer PE™ and
spun for 1 minute at 14,000rpm. The column was placed in a clean centrifuge tube and
50 ul of water was added. The column is allowed to sit for 2 minutes and then spun at
14,000rpm for 2 minutes. This DNA was then sequence verified using the Bodipy
sequence protocol previously described.
This verified and purified PCR product was then used for random primer labeling
using Amersham's Rediprime II kit: The PCR product was diluted to 50 ng in 45 ul TE
(10 roM Tris, pH 8.0, 1 roM EDTA) and denatured at 95° C for 5 minutes. The sample
was then snap cooled on ice and added to the Rediprime 2 reaction tube which contained
a buffered solution of dATP, dGTP, dTIP, endonuclease free klenow enzyme and
random primers in a dried, stabilized form. 5 ul of Redivue ezp) dCTP is added to the
reaction tube ancjAhe tube is mixed and incubated for 30 minutes at 37° C. The reaction
was stopped by the addition of 5ul of 0.2M EDTA. The sample was then denatured at
95° C for 5 minutes. The sample was then snap cooled on ice and purified using a
Microspin G-25 column from Pharmacia Biotech.
A Microspin G-25 column was prepared by resuspending the resin by gentle
vortexing. The cap was loosened and the column is spun at 735 x g for 1 minute. The
column was then placed in a clean eppendorf tube and the labeled reaction was added to
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the resin. The column was spun at 735 x g for 2 minutes and the colu~n was then
discarded. The flow through is the labeled probe. 1 ul of this probe was used to measure
counts per million(CPM). After determining the CPM of each probe, a hybridization was
set up on a multiple tissue dot blot (Figure 18) and several multiple tissue brain blots
(Figure 19).
Probes for the alternatively spliced 5'-UTR's of neuropeptide Yl were isolated
and labeled differently. Probes were designed using the sequence published by Ball et al.
in 1995. Oligonucleotides 80 bases in length were designed and synthesized as the
antisense of the three alternatively spliced exons of neuropeptide Y Yl receptor. These
were synthesized and gel purified by' Gibco and shipped lyophilized. Primers were
resuspended to 100 nglul and end labeled using Promega's DNA 5' end-labeling system
phosphorylation reaction. In this reaction, 100 ng of oligonucleotide"is combined in a 50
ul reaction with 5 ul of T4 PNK lOX buffer, 7 ul of garnma-32P ATP (3,000 Cilmmole),
1 ul of T4 polynucleotide kinase(lOu/ul). This reaction was incubated for 30 minutes at
37° C. The reaction is stopped by the addition of 5ul of 0.2M EDTA. The sample is then
denatured at 95° C for 5 minutes. The sample was then snap cooled on ice and purified
using a Microspin G-25 column fromPharmacia Biotech.
A Microspin G-25 column was prepared by resuspending the resin by gentle
vortexing. The cap was loosened and the column is spun at 735 x g for 1 minute. The
column was then placed in a clean eppendorf tube and the labeled reaction was added to
the resin. The column was spun at 735 x g for 2 minutes and the column was then
discarded.
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Clontech's RNA Dot Blot
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Figure 19. Clontech's RNA Dot Blot used for tissue specific expression
analysis of the coding regions of Neuropeptide Yl and Y5.
Clontech's Multiple Tissue Northern Blots
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Figure 20. Brain regions included in Clontech's Multiple Tissue Northern Blots
that were used for analysis with the Neuropeptide Yl and Y5 receptor probes.
The flow through was the labeled probe. 1ul of this wa used to measure counts per
million(CPM). After determining the CPM of each probe, a hybridization was set up on
a multiple tissue dot blot (Figure 18) and several multiple tissue brain blots (Figure 19).
Hybridization of peR Probes to Dot Blots
The blot was placed in a 250 ml hybridization bottle and 10 mlof 65° C
ExpressHyb solution(Clontech) containing 100 ug denatured sheared salmon testes
DNA(Sigma) was added to the bottle. The bottle was rotated in a 65° C incubator for 30
minutes. The radiolabeled and denatured probe was added to an Expresshyb/salmon
testes DNA solution and mixed. The 10 ml of pre-hybridization solution was poured out
of the bottle and was replaced with the 5 ml of hybridization solution containing the
probe which has been heated to 65° C. The probe was hybridized overnight at 65° C with
continuous agitation. The hybridization solution was poured off and was replaced with
100 ml of wash solution 1(0.3 M NaCl, 0'.03 M Na3Citrate, 1% SDS). The blot was
washed for 20 minutes at 65° C with continuous agitation. This wash step was repeated
four times. The blot was then washed for 20 minutes at 55° C with 100 ml pre-warmed
wash solution 2 (0.015 M NaCI, 0.0015 M Na3Citrate, 0.5% SDS). This wash procedure
was repeated once. After washing, the blot was removed from the bottle and immediately
wrapped in plastic wrap and exposed to Kodak's X-OMAT film for 24 hours.
Hybridization of Oligonucleotide Probes to Dot Blots
The blot was placed in a 250 ml hybridization bottle and 10 ml of 37° C
ExpressHyb solution (Clontech) containing 100 ug denatured sheared salmon testes
DNA(Sigma) was added to the bottle. The bottle was rotated in a 37° C i~cubator for 30
minutes. The radiolabeled and denatured probe was added to an Expresshyb/salmon
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testes DNA solution and mixed. The 10 ml of pre-hybridization solution was poured out
of the bottle and was replaced with the 5 ml of hybridization solution containing the
probe which has been heated to 37° C. The probe was hybridized overnight at 37° C with
continuous agitation. The hybridization solution was poured off and was replaced with
100 ml of wash solution 1 (0.3 M NaCI, 0.03 M Na3Citrate, 1% SDS). The blot was
washed for 20 minutes at 25° C with continuous agitation. This wash step was repeated
four times. The blot was then washed for 20 minutes at 25°C with 100 ml pre-warmed
wash solution 2 (0.015 M NaCl, 0.0015 M Na3Citrate, 0.5% SDS). This wash procedure
was repeated once. After washing, the blot was removed from the bottle and immediately
wrapped in plastic wrap and exposed to Kodak's X-OMAT film for 24 hours.
Hybridization of peR Probes to Multiple Tissue Northern Blot
The blot was placed in a 2~0 ml hybridization bottle and 10 ml of 68° C
ExpressHyb solution (Clontech) was added to the bottle. The bottle was rotated in a 68°
C incubator for 30 minutes. The radiolabeled and denatured probe was added to 5 ml of
ExpressHyb solution and mixed. The 10 ml of pre-hybridization solution was poured out
of the bottle and was replaced with the 5 ml of hybridization solution containing the
probe which has been heated to 68° C. The probe was hybridized overnight at 68° C with
continuous agitation. The hybridization solution was poured out and the blot was washed
with 100 ml of wash solution 1(0.3M NaCl, 0.03M Sodium Citrate pH 7.0,0.05% SDS)
for 20 minutes at room temperature. This wash step was repeated twice. The blot was
then washed with 100 ml of wash solution 2 (0.015M NaCl, 0.0015M sodium citrate pH
7.0,0.1 %SDS) at 50° C for 20 minutes. This wash step was repeated once. The wash
. 4S-
solution was poured off and the blot was immediately wrapped in plastic wrap and
exposed to Kodak's X-OMAT film for 5 days.
Hybridization of Oligonucleotide Probes to Multiple Tissue Northern Blot
The blot was placed in a 250 ml hybridization bottle and 10 ml of 37° C
.ExpressHyb solution (Clontech) was added to the bottle. The bottle was rotated in a 37°
C incubator for 30 minutes. The radiolabeled and denatured probe was added to 5 ml of
ExpressHyb solution and mixed. The 10 ml of pre-hybridization solution was poured out
of the bottle and was replaced with the 5 ml of hybridization solution containing the
probe which has. been heated to 37° C. The probe was hybridized overnight at 37° C with
continuous agitation. The hybridization solution was poured out and the blot was washed
with 100 ml of wash solution 1(O.3M NaCI, 0.03M Sodium Citrate pH 7.0,0.05% SDS)
for 20 minutes at room temperature. This wash step was repeated twice. The blot was
then washed with 100 ml of wash solution 2 (0.015M NaCl, 0.0015M sodium citrate pH
7.0,0.1%SDS) at room temperature for 20 minutes. This wash step was repeated once.
The wash solution was poured off and the blot was immediately wrapped in plastic wrap
and exposed to Kodak's X-OMAT film for 5 days.
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RESULTS
Sequencing of the NPY YI Receptor Gene
DNA from 204 patients was isolated and the neuropeptide Y Yl receptor gene
was amplified using PCR and the primers listed in Table 1. Three PCR products were
generated which gave complete coverage of the coding region of the Yl receptor gene
(figure 2). A forward and areverse sequencing reaction was set up on each PCR product
to provide redundant coverage of the sequence for the entire coding region of the gene.
These sequencing reactions were imported into and aligned in a computer alignment
program called Sequencher (Figure 15). The sequencing chromatograms were then
. analyzed by eye to determine the presence of any heterozygous polymorphisms. In
,
addition the consensus sequence of each individual's DNA was compared to the sequence
of all other patients to determine the presence of homozygous polymorphisms (Figure
16). Within the coding region of neuropeptideY Yl receptor gene of the 204 patients
screened, there were three single nucleotide polymorphisms (SNPs) found as well as one
SNP found 14 bp upstream of the start methionine (Figure 21-24 and Table 4). Table 4
shows that mutation 1 is a silent mutation within transmembrane domain 4 and mutation
2 is a valine to a methionine substitution in transmembrane domain 5, each' found in only
one patient. Mutation 3 however is a mutation found in nearly one percent of the patients
and is located in the final intracellular region towards the carboxy-terminus of the
protein. This mutation is a lysine to a threonine substitution. In addition, mutation 4
which is located 14 bp upstream of th~tart codon, was found to have a frequency of
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Neuropeptide Y Yl Receptor Gene Mutation #1
2870-NPV lldoubleheterol
[!]8 8 ~01:';!":w ::h:··),:,.,t·)"1(:":.; II!!·!!:: ;':,;t,~; II ;·;t·1~.r.'~·::(·';!N·;' I
~~ npZ870..6061 .rZOO1mar99d2 .abi
~~ npZ870..6061 .sOOO1mar99d2 ,abi
i~ npZ870..6263 .r2027jan9geZ.abi I~TTT GGGTCC TTGCT GT GGCT TCIT CTTTGCC TT TCCTG ATCTACCAAGTAAT GAC TGAT GAGCCGTT CC AAAATGT AACACT TGATGC(
~~ npZ870..6Z63.s0027jan9ge2.abi IATTTGGGTCCTTGCTGTGGCTTCIrCTTTGCCTTTCCTGATCTACCAAGTAATGACTGATGAGCCGTTCCAAAATGTAACACTTGATGC(
IE2 frag bases selecled at
consensus position 558.
g!i
540U IS50 1560 1570 1580 1590---\000 1610 1620!
~T.~.~~G.G~~~.T~~C.~.~:r.G.G,C:r:r.~.tr~.:r.~:r~,~.C:r:r~.C~r.G.A:r~.~.A~~.~.~~r.~~:rG.~~:rG.~.~~A.~.C~~.~!~~.~.~~A,~.~:r~.~.~~~.~.~~~.~.~~~
+ ~
---J
ChromatDorams from 2870-NPYI (doubleheterol~~~~~~~~~~ig
Ul
np2870.1>263.rZ027jan9geZ.abi 3Z51 of 570 ,110
T GC T GT GAT T T GG GT C C T T GC T GT GGC T T C T C T T T GC C T T T C C T GAT C T A C C A AGT A.A T G
RJaRJRJIRRRJJJR aRRJaRJRJJaRRa~RaRRRJBaRRRaaRJTRaRTaaTTJRTTRJ
Figure 21. Sequencher alignment and chromatogram trace of patient
2870. Y indicates a heterozygous mutation of a cytidine and a thymidine.
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Neuropeptide Y YI Receptor Gene Mutation #2
Figure 22. Sequencher alignment and chromatogram trace of patient
3397. R indicates the presence of a heterozygous mutation between
an adenosine and guanosine nucleotide.
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Neuropeptide Y Yl Receptor Gene Mutation#3
Figure 23. Sequencher alignment and chromatogram trace of the NPY Y1
receptor gene for patient 114A. M represents a heterozygous mutation
between an adenosine and a cytidine.
Neuropeptide Y YI Receptor Gene Mutation #4
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Figure 24. Sequencher alignment and chromatogram trace of patient
989A. Y indicates a heterozygous mutation of a cytidine and thymidine.
This mutation is found 14 bp upstream of the start codon.
NEUROPEPTIDE Y Yi RECEPTOR GENE SINGLE NUCLEOTDE POLYMORPHISMS
Mutation Amino Acid Position Nuclebtide codon change Amino Acid change Frequency
of384 (From/To) (FromlTo)
1 169(Transmembrane Region 4) TCCITCT Serine/Serine 2/204=0.49%
2 217(Transmembrane Region 5) GTG/ATG ValinelMethionine 1/204=0.24%
lJ\
lJ\
3 374(Final Intracellular Domain) AAA/ACA LysinelThreonine 4/204=0.98%
-
4 -14bp upstream of start AUG CAACC/CAATC 12/204=2.94%
Table 4. NPY Y1 receptor gene mutations. Mutation 1-3 are located in the coding
region of the receptor. Mutation 4 is located 14 bp upstream of the start methionine.
nearly three percent in the patients screened. The three coding mutations as they are
located in the protein can be seen in figure 25.
Sequencing of the NPY Y5 Receptor Gene
DNA from 203 patients was isolated and the neuropeptide Y Y5 receptor gene
was amplified using PCR and the primers listed in Table 1. PCR amplification of the Y5
receptor gene was done similarly to the Y1 gene. A forward and a reverse sequencing
reaction was set up on each peR product to provide redundant coverage of the sequence
for the entire coding region of the gene. Sequences were analyzed for heterozygous
mutations using the computer software package previously described. In addition, the
consensus sequence of each individuals DNA was compared to the sequence of all other
patients to determine the presence of homozygous polymorphisms (Figure 17). Within
the coding region of neuropeptide Y Y5 receptor gene of the 203 patients screened, there
were three single nucleotide polymorphisms (SNPs) found (Figures 26-28 and Table 5).
All SNPs are heterozygous mutations. Mutations 1 and 2 were found in only one patient
of the 203 screened. Mutation 1 is a arginine to a cysteine substitution and mutation 2 is
a silent mutation. Mutation 3 which is also a silent mutation was found in 29 patients all
of which are heterozygous for the SNP. The three coding mutations as they are located in
the protein can be seen in figure 29.
,
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Figure 26. Sequencher alignment and chromatogram trace for patient
528A. Y represents a heterozygous mutation of a cytidine and a thymidine.
Neuropeptide Y Y5 Receptor Gene Mutation #2
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Figure 27.Sequencher alignment and chromatogram trace for patient
421A. Y represents a heterozygous mutation of a cytidine and a thymidine.
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Figure 28. Sequencher alignment and chromatogram trace of patient
PL90. R indicates the presence of a heterozygous mutation between
an adenosine and guanosine nucleotide.
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NEUROPEPTIDE Y Y5 RECEPTOR GENE SINGLE NUCLEOTDE POLYMORPHISMS
Amino Acid Position Nucleotide codon change Amino Acid change Frequency
of 445 (FromITo) (FromITo)
132(Transmembrane Region 3) CGT/TGT Arginine/Cysteine 1/203=0.24%
217(Extracellular loop 2) TAT/TAC Tyrosi ne/Tyrosine 1/203=0.24%
426(Final Intracellular Domain) GGG/GGA Glycine/Glycine 29/203=7.14%
Table 5. NPY Y5 gene polymorphisms and their frequency in the tested
Population. All mutations are within the coding region of the receptor gene.
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Figure 29. NPY YS receptor protein structure. Red
arrows indicate positions of mutations.
62
Tissue Specific Expression of NPY Yl Coding mRNA
A 500 bp DNA PCR product from within the coding region of the NPY Yl
receptor gene was labeled using a random primer labeling system and used as a probe to
. perform a northern analysis on a multiple tissue Dot Blot. 5x106 counts per ml was used
to probe the blot. Dot Blot analysis showed expression of the coding region of NPY Yl
in various brain regions including the amygdala, caudate nucleus, cerebral cortex, frontal
lobe, occipital lobe, putainen temporal lobe and subthalamic nucleus. The greatest
amount of expression was seen in the peripheral tissues and included the aorta, uterus,
pancreas, pituitary gland, adrenal gland, thyroid gland, mammary gland, kidney liver and
spleen. In addition high expression was seen in fetal brain, kidney and spleen. (Figure
30)
Because NPY Yl receptor expression was seen in the brain regions, a multiple
. tissue northern analysis was done using two separate brain specific blots to look for size
differences and additional brain region expression. NPY Yl receptor is a 2.7 Kb
transcript that is seen ~n the cerebral cortex, medulla, occipital pole, frontal lobe,
temporal lobe, putamen, amygdala, caudate nucleus, hippocampus, thalamus and to a
lesser degree in the cerebellum and the spinal cord (Figure 31).
Tissue Specific Expression of the three alternatively spliced 5' exons of NPY Yl
Complementary oligonucleotides were designed against the three alternatively
spliced exons of NPY Yl receptor mRNA. These probes were end-labeled and
hybridized to two different brain region multiple tissue northern blots. Each of the three
alternatively spliced exons (lA, lB and lC) was hybridized separately to the two
multiple tissue brain blots. Each transcript is 2.7Kb and the three 5' exons are found to
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RNA Dot Blot with Neuropeptide Yl
Figure 30. RNA Dot Blot of the tissue specific expression
of the Neuropeptide Y Yl coding region
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RNA Dot Blot with Neuropeptide Yl
Figure 30. RNA Do,t Blot of the tissue specific expression
of the Neuropeptide Y Yl coding region
MTN with Neuropeptide Yl
~
II) II)
t:: II) .0
0
-
II) 0
8 u "E 0 .0 .....10... 0
.2 "@ 0 ~ ....l - .:::U C':Ja:l l-< C':J ..... ~ l-< II).0 - '0.. 0 8.0 II) ;:; ~ ..... 0-Il) l-<
"0 .::: '0 .::: 8 C':Jl-< II) 0 .....II) U II) 's. () d:: ~ 0:u :;E fZJ 0
C':J
~
1'0
;>.,
~
Vi
~
II)
u
~
z
*
"0g
U
8
~
Vi
.Q
~
u
Vi
~
E<
o
u
Vi
t
()
o
0-
0-
:E
.:::
.§
t:Q
II)
"0
~
e
OJ)
Z
C':J
.~
.....
Vi
-§
fZJ
Vi
~
~
ES
Si 4.4-,
2.4- ..
1.35 --&.
.~.
«
Kb
9.5-.
7.5-
4.4-
2.4-'
1.35--
Figure 31. Brain region multiple tissue northerns of the coding region
of neuropeptide Y Y1. The transcript is 2.7 Kb in size.
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be alternatively expressed. Exon IA is expressed in all regions of the brain studied with
the highest expression found in the medulla and thalamus (Figure 32). Exon IB
expression was not found in any regions of the brain using several hybridization and
wash conditions. Exon IC, which is contained within the coding region of the NPY Y5
receptor gene and transcribed from the opposite strand, is expressed in the medulla,
spinal cord, amygdala, caudate nucleus, hippocampus, substantia nigra and the thalamus.
(Figure 33)
Tissue Specific Expression of NPY Y5 Coding mRNA
A 500 bp DNA PCR product from within the coding region of the NPY Y5
receptor gene was labeled and used as a probe similarly to the aYI probe. Dot blot
analysis showed expression of the coding region of NPY Y5 in various brain regions
including the amygdala, caudate nucleus, cerebral cortex, frontal lobe, hippocampus,
occipital lobe, putamen, temporal lobe, thalamus, subthalamic nucleus and spinal cord.
The Y5 receptor was also expressed in peripheral tissues including the aorta, testes,
adrenal gland, mammary gland, kidney and spleen. The receptor mRNA was also
expressed in fetal brain and spleen. (Figure 34)
Because NPY Y5 receptor expression was seen in the brain regions, a multiple
tissue northern analysis was done using two separate brain specific blots to look for size
differences and additional brain region expression. NPY Y5 receptor is a 2.6 Kb
transcript that is seyn in the cerebral cortex, medulla, frontal lobe, temporal lobe,
amygdala, whole brain, substantia nigra with the highest expression found in the occipital
pole, putamen and the caudate nucleus. (Figure 35). Or
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Multiple Tissue Northern with Neuropeptide Yl Exon lA
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Figure 32. Multiple Tissue Northern using Exon lA of Neuropeptide Y YI receptor as
the probe. Tissue specific expression of the exon can be seen in various regions of
the brain.
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Figure 32. Multiple Tissue Northern using Exon lA of Neuropeptide Y Yl receptor as
the probe. Tissue specific expression of the exon can be seen in various regions of
the brain.
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Figure 33. Multiple Tissue Northern using Exon Ie of Neuropeptide Y Yl receptor as
the probe. Tissue specific expression of the exon can be seen in various regions of
the brain.
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Figure 33. Multiple Tissue Northern using Exon Ie of Neuropeptide Y Y1 receptor as
the probe. Tissue specific expression of the exon can be seen in various regions of
the brain.
RNA Dot Blot with Y5 Coding
Figure 34. RNA dot blot of NPY YS receptor coding region
expression. Spots indicate positive expression of the receptor mRNA.
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RNA Dot Blot with Y5 Coding
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Figure 34. RNA dot blot of NPY Y5 receptor coding region
expression. Spots indicate positive expression of the receptor mRNA.
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Discussion
Sequencing is the most accurate method available for screening for
polymorphisms within genomic DNA. In addition, due to the production of uniform
peak heights, Bodipy sequencing chemistry is the most accurate chemistry which can be
used when looking for heterozygous mutations. Therefore, Bodipy sequencing chemistry
was used as the tool to screen patients for single nucleotide polymorphisms within the
coding regions of both the neuropeptide Y Y1 and neuropeptide Y Y5 receptor genes.
Experiments have already demonstrated that these receptors are involved in the anabolic
pathway of feeding and it has been suggested that mutations within these genes may
result in obesity (Fan, 1997). It has also been demonstrated that mutations within the
coding region of the melanocortin-4-receptor, involved in the catabolic pathway of
feeding, are either silent or occur at a frequency less than 1%. As a result the
neuropeptide receptors make good candidates for mutation analysis.
There is also preliminary evidence that alternatively spliced 5' -UTRs are involved
in tissue specific expression of the Y1 receptor. In addition, tissue specific expression
studies were needed to understand the roles of both the Y1 and the Y5 receptors.
Northern analysis was used to study the expression patterns of the two receptors using a
multiple tissue dot blot to study the expression in both central and peripheral tissues.
Multiple tissue northerns were then used 10 study expression of the receptors within
various regions of the brain.
Neuropeptide Y YI and Y5 Receptor Polymorphisms
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Polymorphism analysis of the NPY YI and Y5 receptor genes showed three
. mutations within the coding regions of both receptors. All mutations occurred at a
frequency less than one percent. (Table 4 and Table 5) Using patients positive for
angina and schizophrenia provided a diverse gender and ethnic population for
polymorphism analysis. The occurrence of mutations in the population suggests that
mutations within the coding regions of the YI and Y5 receptor genes may be responsible
for the genetic predisposition to develop obesity. Mutation 3 of the YI gene occurred at
approximately I% and was found within the carboxy-terminus of the protein, a region
known to be important for G-Protein binding and phosphorylation. Mutation 2, although
only at 0.25% in frequency was found within the fifth transmembrane domain, an area of
the protein which may be involved with ligand binding. Only one coding mutation
within the Y5 receptor gene was fou!1d. This cysteine/Arginine substitution occurredat a
frequency of 0.2% and is located within the third transmembrane domain, an area of the
protein which may be involved with ligand binding. At this time, little is known about
the downstream elements in the anabolic pathway of feeding, and it is possible that
mutations within the genes coding for these elements may contain additional mutations.
Tissue specific expression of the Neuropeptide Y Y5 receptor gene
Previous experiments showed that expression of the Y5 receptor gene was limited
to the brain and the testes. RNA Dot Blot analysis using the coding region of the Y5
receptor gene as the probe showed expression mainly in the brain but also in several
peripheral tissues. It was also hypothesized that transcription of neuropeptide YI Exon
IC would have a direct inhibitory affect on the transcription of neuropeptide Y5.In some
cases expression of only Y5 or YI exon IC was found. However, in sometissue types,
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such as the medulla, spinal cord, amygdala, caudate nucleus and hippocampus, both
were expressed. This suggests that both receptors can be expressed within the same
tissue, however, they may be expressed in different cell types within these tissues.
Tissue specific expression of the Neuropeptide Y YI receptor gene
_ J
Previous experiments showed that expression of the YI receptor was found
mainly in peripheral tissues. RNA Dot Blot analysis using the coding region of the YI
receptor gene as the probe showed expression mainly in several peripheral tissues but
also in many regions of the brain. Previous evidence suggested that the Y5 receptor was
responsible for central binding of NPY where as YI was the peripheral receptor for Yl.
This new evidence suggests that dual expression of both receptors regulates NPY binding
in both the CNS and the periphery and both receptors are important in controlling the
effect of NPY.
Tissue specific expression of the Neuropeptide Y YI recept.or gene 5' UTRs
Oligonucleotides were synthesized to use as probes to bind specifically to the
three alternatively spliced 5' exons of the neuropeptide Y YI receptor gene. Exon IA
w,as found to be expressed throughout all brain regions studied. Exon IB was not found
in any of the brain regions studied. Several hybridization and wash conditions were used
to identify the expression pattern of this exon without success. This may be due to the
possibility that exon IB is expressed only in peripheral tissue or that exon IB is not an
alternatively expressed exon of YI as suggested (Herzog, 1997). Exon IC, which is
contained within the coding region of Y5 and is transcribed from the opposite strand, was
found to be alternatively expressed. However, as stated earlier, the expression of exon
IC of YI and Y5 occurin the same tissues.
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Conclusion
Obesity in humans does not seem to be' a monogenic disorder, as is the case in
several rodent models. However, several mutations within the coding regions of the
neuropeptide Y Yl and Y5 receptor may be responsible for the genetic predisposition to
develop obesity. Genetic obesity in humans appears to be caused by mutations within
several genes of the feeding pathways, including the leptin, melanocortin-4-receptor,
NPY Yl and NPY Y5.
Northern analysis shows that NPY Yl and Y5 are both expressed in several brain
regions and that both are expressed in some of the same tissues. This suggests that
coordinated expression of both the Yl and Y5 receptor genes does not exist, at the tissue
level, but rather dual expression of these receptors regulate NPY binding in both the CNS
and the periphery and both receptors are important in controlling the effect of NPY. As a
result, one would expect that a mutation causing altered function in either of the two
receptors may cause a predisposition to obesity in humans.
Future Research
An in depth analysis of the expression of the alternatively spliced forms of the Yl
receptor gene is needed in peripheral tissues. This will provide evidence for the
relevance of exon lB. In addition, Rapid Amplification of cDNA Ends(RACE)
experiments need to be performed to determine whether different 5' exons of the Y5
receptor gene exist. If there are in fact alternatively spliced isoforms, a northern analysis
should be done to determine their exp,ression patterns. In addition, a SNP analysis of the
5'UTR's of both receptors in needed to determine whether a mutation is present that
might affect translation of the receptors. Finally, the common promoter region of the two
74
genes should be sequenced to identify putative regulatory elements and to determine
whether other possible isoforms exist.
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